Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/duality-finger-at-us-drug-patent-call-4675188/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/duality-finger-at-us-drug-patent-call-4675188/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/duality-finger-at-us-drug-patent-call-4675188/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/duality-finger-at-us-drug-patent-call-4675188/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7999a0ec8f-trace').style.display = (document.getElementById('cakeErr67f7999a0ec8f-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f7999a0ec8f-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7999a0ec8f-code').style.display = (document.getElementById('cakeErr67f7999a0ec8f-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7999a0ec8f-context').style.display = (document.getElementById('cakeErr67f7999a0ec8f-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f7999a0ec8f-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f7999a0ec8f-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 27140,
		&#039;title&#039; =&gt; &#039;Duality finger at US drug patent call&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists claimed yesterday that the India-US joint statement, issued during Obama&#039;s visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders&#039; consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists said Obama, whose first presidential campaign included a prominent pledge to &amp;quot;break the stranglehold&amp;quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Indian generics have been essential to expanding access to medicines around the world,&amp;quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies&#039; demand for &amp;quot;data exclusivity&amp;quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&amp;quot; said Anand Grover, director of Lawyers&#039; Collective, a network of lawyers in India that has represented patients&#039; groups and challenged certain decisions on patents in courts.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Activists believe India&#039;s existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &amp;quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&amp;quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Representatives of pharmaceutical companies seeking changes in India&#039;s intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &amp;quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 29 January, 2015, http://www.telegraphindia.com/1150129/jsp/nation/story_10575.jsp#.VMncyC7xxpA&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;duality-finger-at-us-drug-patent-call-4675188&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4675188,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 27140,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Duality finger at US drug patent call&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Health,Access to Healthcare,Access to Medicines,generic medicine,generic medicines,Intellectual Property Rights,IPRs,patents&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph


New Delhi: International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.


The activists...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists claimed yesterday that the India-US joint statement, issued during Obama&#039;s visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders&#039; consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists said Obama, whose first presidential campaign included a prominent pledge to &amp;quot;break the stranglehold&amp;quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Indian generics have been essential to expanding access to medicines around the world,&amp;quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies&#039; demand for &amp;quot;data exclusivity&amp;quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&amp;quot; said Anand Grover, director of Lawyers&#039; Collective, a network of lawyers in India that has represented patients&#039; groups and challenged certain decisions on patents in courts.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Activists believe India&#039;s existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &amp;quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&amp;quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Representatives of pharmaceutical companies seeking changes in India&#039;s intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &amp;quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 27140,
	&#039;title&#039; =&gt; &#039;Duality finger at US drug patent call&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists claimed yesterday that the India-US joint statement, issued during Obama&#039;s visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders&#039; consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists said Obama, whose first presidential campaign included a prominent pledge to &amp;quot;break the stranglehold&amp;quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Indian generics have been essential to expanding access to medicines around the world,&amp;quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies&#039; demand for &amp;quot;data exclusivity&amp;quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&amp;quot; said Anand Grover, director of Lawyers&#039; Collective, a network of lawyers in India that has represented patients&#039; groups and challenged certain decisions on patents in courts.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Activists believe India&#039;s existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &amp;quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&amp;quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Representatives of pharmaceutical companies seeking changes in India&#039;s intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &amp;quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 29 January, 2015, http://www.telegraphindia.com/1150129/jsp/nation/story_10575.jsp#.VMncyC7xxpA&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;duality-finger-at-us-drug-patent-call-4675188&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4675188,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 27140
$metaTitle = &#039;LATEST NEWS UPDATES | Duality finger at US drug patent call&#039;
$metaKeywords = &#039;Access to Health,Access to Healthcare,Access to Medicines,generic medicine,generic medicines,Intellectual Property Rights,IPRs,patents&#039;
$metaDesc = &#039;
-The Telegraph


New Delhi: International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.


The activists...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists claimed yesterday that the India-US joint statement, issued during Obama&#039;s visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders&#039; consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists said Obama, whose first presidential campaign included a prominent pledge to &amp;quot;break the stranglehold&amp;quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Indian generics have been essential to expanding access to medicines around the world,&amp;quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies&#039; demand for &amp;quot;data exclusivity&amp;quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&amp;quot; said Anand Grover, director of Lawyers&#039; Collective, a network of lawyers in India that has represented patients&#039; groups and challenged certain decisions on patents in courts.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Activists believe India&#039;s existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &amp;quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&amp;quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Representatives of pharmaceutical companies seeking changes in India&#039;s intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &amp;quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/duality-finger-at-us-drug-patent-call-4675188.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Duality finger at US drug patent call | Im4change.org</title>
    <meta name="description" content="
-The Telegraph


New Delhi: International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.


The activists..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Duality finger at US drug patent call</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph</div><p align="justify"><em>New Delhi: </em>International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.</p><p align="justify">The activists claimed yesterday that the India-US joint statement, issued during Obama's visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.</p><p align="justify">The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders' consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.</p><p align="justify">Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.</p><p align="justify">The activists said Obama, whose first presidential campaign included a prominent pledge to &quot;break the stranglehold&quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.</p><p align="justify">&quot;Indian generics have been essential to expanding access to medicines around the world,&quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.</p><p align="justify">Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies' demand for &quot;data exclusivity&quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.</p><p align="justify">&quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&quot; said Anand Grover, director of Lawyers' Collective, a network of lawyers in India that has represented patients' groups and challenged certain decisions on patents in courts.</p><p align="justify">Activists believe India's existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.</p><p align="justify">Representatives of pharmaceutical companies seeking changes in India's intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.</p><p align="justify">But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&quot;</p><p align="justify">He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7999a0ec8f-trace').style.display = (document.getElementById('cakeErr67f7999a0ec8f-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f7999a0ec8f-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7999a0ec8f-code').style.display = (document.getElementById('cakeErr67f7999a0ec8f-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7999a0ec8f-context').style.display = (document.getElementById('cakeErr67f7999a0ec8f-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f7999a0ec8f-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f7999a0ec8f-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 27140,
		&#039;title&#039; =&gt; &#039;Duality finger at US drug patent call&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists claimed yesterday that the India-US joint statement, issued during Obama&#039;s visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders&#039; consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists said Obama, whose first presidential campaign included a prominent pledge to &amp;quot;break the stranglehold&amp;quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Indian generics have been essential to expanding access to medicines around the world,&amp;quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies&#039; demand for &amp;quot;data exclusivity&amp;quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&amp;quot; said Anand Grover, director of Lawyers&#039; Collective, a network of lawyers in India that has represented patients&#039; groups and challenged certain decisions on patents in courts.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Activists believe India&#039;s existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &amp;quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&amp;quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Representatives of pharmaceutical companies seeking changes in India&#039;s intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &amp;quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 29 January, 2015, http://www.telegraphindia.com/1150129/jsp/nation/story_10575.jsp#.VMncyC7xxpA&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;duality-finger-at-us-drug-patent-call-4675188&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4675188,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 27140,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Duality finger at US drug patent call&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Health,Access to Healthcare,Access to Medicines,generic medicine,generic medicines,Intellectual Property Rights,IPRs,patents&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph


New Delhi: International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.


The activists...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists claimed yesterday that the India-US joint statement, issued during Obama&#039;s visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders&#039; consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists said Obama, whose first presidential campaign included a prominent pledge to &amp;quot;break the stranglehold&amp;quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Indian generics have been essential to expanding access to medicines around the world,&amp;quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies&#039; demand for &amp;quot;data exclusivity&amp;quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&amp;quot; said Anand Grover, director of Lawyers&#039; Collective, a network of lawyers in India that has represented patients&#039; groups and challenged certain decisions on patents in courts.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Activists believe India&#039;s existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &amp;quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&amp;quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Representatives of pharmaceutical companies seeking changes in India&#039;s intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &amp;quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 27140,
	&#039;title&#039; =&gt; &#039;Duality finger at US drug patent call&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists claimed yesterday that the India-US joint statement, issued during Obama&#039;s visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders&#039; consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists said Obama, whose first presidential campaign included a prominent pledge to &amp;quot;break the stranglehold&amp;quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Indian generics have been essential to expanding access to medicines around the world,&amp;quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies&#039; demand for &amp;quot;data exclusivity&amp;quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&amp;quot; said Anand Grover, director of Lawyers&#039; Collective, a network of lawyers in India that has represented patients&#039; groups and challenged certain decisions on patents in courts.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Activists believe India&#039;s existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &amp;quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&amp;quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Representatives of pharmaceutical companies seeking changes in India&#039;s intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &amp;quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 29 January, 2015, http://www.telegraphindia.com/1150129/jsp/nation/story_10575.jsp#.VMncyC7xxpA&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;duality-finger-at-us-drug-patent-call-4675188&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4675188,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 27140
$metaTitle = &#039;LATEST NEWS UPDATES | Duality finger at US drug patent call&#039;
$metaKeywords = &#039;Access to Health,Access to Healthcare,Access to Medicines,generic medicine,generic medicines,Intellectual Property Rights,IPRs,patents&#039;
$metaDesc = &#039;
-The Telegraph


New Delhi: International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.


The activists...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists claimed yesterday that the India-US joint statement, issued during Obama&#039;s visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders&#039; consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists said Obama, whose first presidential campaign included a prominent pledge to &amp;quot;break the stranglehold&amp;quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Indian generics have been essential to expanding access to medicines around the world,&amp;quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies&#039; demand for &amp;quot;data exclusivity&amp;quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&amp;quot; said Anand Grover, director of Lawyers&#039; Collective, a network of lawyers in India that has represented patients&#039; groups and challenged certain decisions on patents in courts.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Activists believe India&#039;s existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &amp;quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&amp;quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Representatives of pharmaceutical companies seeking changes in India&#039;s intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &amp;quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/duality-finger-at-us-drug-patent-call-4675188.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Duality finger at US drug patent call | Im4change.org</title>
    <meta name="description" content="
-The Telegraph


New Delhi: International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.


The activists..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Duality finger at US drug patent call</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph</div><p align="justify"><em>New Delhi: </em>International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.</p><p align="justify">The activists claimed yesterday that the India-US joint statement, issued during Obama's visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.</p><p align="justify">The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders' consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.</p><p align="justify">Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.</p><p align="justify">The activists said Obama, whose first presidential campaign included a prominent pledge to &quot;break the stranglehold&quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.</p><p align="justify">&quot;Indian generics have been essential to expanding access to medicines around the world,&quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.</p><p align="justify">Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies' demand for &quot;data exclusivity&quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.</p><p align="justify">&quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&quot; said Anand Grover, director of Lawyers' Collective, a network of lawyers in India that has represented patients' groups and challenged certain decisions on patents in courts.</p><p align="justify">Activists believe India's existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.</p><p align="justify">Representatives of pharmaceutical companies seeking changes in India's intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.</p><p align="justify">But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&quot;</p><p align="justify">He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7999a0ec8f-trace').style.display = (document.getElementById('cakeErr67f7999a0ec8f-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f7999a0ec8f-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7999a0ec8f-code').style.display = (document.getElementById('cakeErr67f7999a0ec8f-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f7999a0ec8f-context').style.display = (document.getElementById('cakeErr67f7999a0ec8f-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f7999a0ec8f-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f7999a0ec8f-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 27140,
		&#039;title&#039; =&gt; &#039;Duality finger at US drug patent call&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists claimed yesterday that the India-US joint statement, issued during Obama&#039;s visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders&#039; consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists said Obama, whose first presidential campaign included a prominent pledge to &amp;quot;break the stranglehold&amp;quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Indian generics have been essential to expanding access to medicines around the world,&amp;quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies&#039; demand for &amp;quot;data exclusivity&amp;quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&amp;quot; said Anand Grover, director of Lawyers&#039; Collective, a network of lawyers in India that has represented patients&#039; groups and challenged certain decisions on patents in courts.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Activists believe India&#039;s existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &amp;quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&amp;quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Representatives of pharmaceutical companies seeking changes in India&#039;s intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &amp;quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 29 January, 2015, http://www.telegraphindia.com/1150129/jsp/nation/story_10575.jsp#.VMncyC7xxpA&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;duality-finger-at-us-drug-patent-call-4675188&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4675188,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 27140,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Duality finger at US drug patent call&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;Access to Health,Access to Healthcare,Access to Medicines,generic medicine,generic medicines,Intellectual Property Rights,IPRs,patents&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph


New Delhi: International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.


The activists...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists claimed yesterday that the India-US joint statement, issued during Obama&#039;s visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders&#039; consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists said Obama, whose first presidential campaign included a prominent pledge to &amp;quot;break the stranglehold&amp;quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Indian generics have been essential to expanding access to medicines around the world,&amp;quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies&#039; demand for &amp;quot;data exclusivity&amp;quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&amp;quot; said Anand Grover, director of Lawyers&#039; Collective, a network of lawyers in India that has represented patients&#039; groups and challenged certain decisions on patents in courts.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Activists believe India&#039;s existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &amp;quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&amp;quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Representatives of pharmaceutical companies seeking changes in India&#039;s intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &amp;quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 27140,
	&#039;title&#039; =&gt; &#039;Duality finger at US drug patent call&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists claimed yesterday that the India-US joint statement, issued during Obama&#039;s visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders&#039; consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists said Obama, whose first presidential campaign included a prominent pledge to &amp;quot;break the stranglehold&amp;quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Indian generics have been essential to expanding access to medicines around the world,&amp;quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies&#039; demand for &amp;quot;data exclusivity&amp;quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&amp;quot; said Anand Grover, director of Lawyers&#039; Collective, a network of lawyers in India that has represented patients&#039; groups and challenged certain decisions on patents in courts.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Activists believe India&#039;s existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &amp;quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&amp;quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Representatives of pharmaceutical companies seeking changes in India&#039;s intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &amp;quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&amp;quot;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 29 January, 2015, http://www.telegraphindia.com/1150129/jsp/nation/story_10575.jsp#.VMncyC7xxpA&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;duality-finger-at-us-drug-patent-call-4675188&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4675188,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 27140
$metaTitle = &#039;LATEST NEWS UPDATES | Duality finger at US drug patent call&#039;
$metaKeywords = &#039;Access to Health,Access to Healthcare,Access to Medicines,generic medicine,generic medicines,Intellectual Property Rights,IPRs,patents&#039;
$metaDesc = &#039;
-The Telegraph


New Delhi: International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.


The activists...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;em&gt;New Delhi: &lt;/em&gt;International health activists have joined their Indian counterparts in decrying what they say are Barack Obama&#039;s dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists claimed yesterday that the India-US joint statement, issued during Obama&#039;s visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders&#039; consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists said Obama, whose first presidential campaign included a prominent pledge to &amp;quot;break the stranglehold&amp;quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Indian generics have been essential to expanding access to medicines around the world,&amp;quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies&#039; demand for &amp;quot;data exclusivity&amp;quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&amp;quot; said Anand Grover, director of Lawyers&#039; Collective, a network of lawyers in India that has represented patients&#039; groups and challenged certain decisions on patents in courts.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Activists believe India&#039;s existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &amp;quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&amp;quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Representatives of pharmaceutical companies seeking changes in India&#039;s intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &amp;quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&amp;quot;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/duality-finger-at-us-drug-patent-call-4675188.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Duality finger at US drug patent call | Im4change.org</title>
    <meta name="description" content="
-The Telegraph


New Delhi: International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.


The activists..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Duality finger at US drug patent call</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph</div><p align="justify"><em>New Delhi: </em>International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.</p><p align="justify">The activists claimed yesterday that the India-US joint statement, issued during Obama's visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.</p><p align="justify">The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders' consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.</p><p align="justify">Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.</p><p align="justify">The activists said Obama, whose first presidential campaign included a prominent pledge to &quot;break the stranglehold&quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.</p><p align="justify">&quot;Indian generics have been essential to expanding access to medicines around the world,&quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.</p><p align="justify">Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies' demand for &quot;data exclusivity&quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.</p><p align="justify">&quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&quot; said Anand Grover, director of Lawyers' Collective, a network of lawyers in India that has represented patients' groups and challenged certain decisions on patents in courts.</p><p align="justify">Activists believe India's existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.</p><p align="justify">Representatives of pharmaceutical companies seeking changes in India's intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.</p><p align="justify">But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&quot;</p><p align="justify">He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 27140,
		'title' => 'Duality finger at US drug patent call',
		'subheading' => '',
		'description' => '<div align="justify">
-The Telegraph
</div>
<p align="justify">
<em>New Delhi: </em>International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.
</p>
<p align="justify">
The activists claimed yesterday that the India-US joint statement, issued during Obama's visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.
</p>
<p align="justify">
The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders' consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.
</p>
<p align="justify">
Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.
</p>
<p align="justify">
The activists said Obama, whose first presidential campaign included a prominent pledge to &quot;break the stranglehold&quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.
</p>
<p align="justify">
&quot;Indian generics have been essential to expanding access to medicines around the world,&quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.
</p>
<p align="justify">
Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies' demand for &quot;data exclusivity&quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.
</p>
<p align="justify">
&quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&quot; said Anand Grover, director of Lawyers' Collective, a network of lawyers in India that has represented patients' groups and challenged certain decisions on patents in courts.
</p>
<p align="justify">
Activists believe India's existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.
</p>
<p align="justify">
Representatives of pharmaceutical companies seeking changes in India's intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.
</p>
<p align="justify">
But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&quot;
</p>
<p align="justify">
He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.
</p>',
		'credit_writer' => 'The Telegraph, 29 January, 2015, http://www.telegraphindia.com/1150129/jsp/nation/story_10575.jsp#.VMncyC7xxpA',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'duality-finger-at-us-drug-patent-call-4675188',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4675188,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 27140,
	'metaTitle' => 'LATEST NEWS UPDATES | Duality finger at US drug patent call',
	'metaKeywords' => 'Access to Health,Access to Healthcare,Access to Medicines,generic medicine,generic medicines,Intellectual Property Rights,IPRs,patents',
	'metaDesc' => '
-The Telegraph


New Delhi: International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.


The activists...',
	'disp' => '<div align="justify">-The Telegraph</div><p align="justify"><em>New Delhi: </em>International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.</p><p align="justify">The activists claimed yesterday that the India-US joint statement, issued during Obama's visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.</p><p align="justify">The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders' consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.</p><p align="justify">Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.</p><p align="justify">The activists said Obama, whose first presidential campaign included a prominent pledge to &quot;break the stranglehold&quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.</p><p align="justify">&quot;Indian generics have been essential to expanding access to medicines around the world,&quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.</p><p align="justify">Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies' demand for &quot;data exclusivity&quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.</p><p align="justify">&quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&quot; said Anand Grover, director of Lawyers' Collective, a network of lawyers in India that has represented patients' groups and challenged certain decisions on patents in courts.</p><p align="justify">Activists believe India's existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.</p><p align="justify">Representatives of pharmaceutical companies seeking changes in India's intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.</p><p align="justify">But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&quot;</p><p align="justify">He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 27140,
	'title' => 'Duality finger at US drug patent call',
	'subheading' => '',
	'description' => '<div align="justify">
-The Telegraph
</div>
<p align="justify">
<em>New Delhi: </em>International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.
</p>
<p align="justify">
The activists claimed yesterday that the India-US joint statement, issued during Obama's visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.
</p>
<p align="justify">
The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders' consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.
</p>
<p align="justify">
Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.
</p>
<p align="justify">
The activists said Obama, whose first presidential campaign included a prominent pledge to &quot;break the stranglehold&quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.
</p>
<p align="justify">
&quot;Indian generics have been essential to expanding access to medicines around the world,&quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.
</p>
<p align="justify">
Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies' demand for &quot;data exclusivity&quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.
</p>
<p align="justify">
&quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&quot; said Anand Grover, director of Lawyers' Collective, a network of lawyers in India that has represented patients' groups and challenged certain decisions on patents in courts.
</p>
<p align="justify">
Activists believe India's existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.
</p>
<p align="justify">
Representatives of pharmaceutical companies seeking changes in India's intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.
</p>
<p align="justify">
But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&quot;
</p>
<p align="justify">
He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.
</p>',
	'credit_writer' => 'The Telegraph, 29 January, 2015, http://www.telegraphindia.com/1150129/jsp/nation/story_10575.jsp#.VMncyC7xxpA',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'duality-finger-at-us-drug-patent-call-4675188',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4675188,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {},
		(int) 7 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 27140
$metaTitle = 'LATEST NEWS UPDATES | Duality finger at US drug patent call'
$metaKeywords = 'Access to Health,Access to Healthcare,Access to Medicines,generic medicine,generic medicines,Intellectual Property Rights,IPRs,patents'
$metaDesc = '
-The Telegraph


New Delhi: International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.


The activists...'
$disp = '<div align="justify">-The Telegraph</div><p align="justify"><em>New Delhi: </em>International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India.</p><p align="justify">The activists claimed yesterday that the India-US joint statement, issued during Obama's visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.</p><p align="justify">The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders' consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas.</p><p align="justify">Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries.</p><p align="justify">The activists said Obama, whose first presidential campaign included a prominent pledge to &quot;break the stranglehold&quot; of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India.</p><p align="justify">&quot;Indian generics have been essential to expanding access to medicines around the world,&quot; Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement.</p><p align="justify">Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies' demand for &quot;data exclusivity&quot; that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules.</p><p align="justify">&quot;Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries,&quot; said Anand Grover, director of Lawyers' Collective, a network of lawyers in India that has represented patients' groups and challenged certain decisions on patents in courts.</p><p align="justify">Activists believe India's existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. &quot;It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India,&quot; said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer.</p><p align="justify">Representatives of pharmaceutical companies seeking changes in India's intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules.</p><p align="justify">But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. &quot;India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs.&quot;</p><p align="justify">He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Duality finger at US drug patent call

-The Telegraph New Delhi: International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India. The activists claimed yesterday that the India-US joint statement, issued during Obama's visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies. The statement had said both countries reiterated their interest in sharing information and best practices on intellectual property rights issues, and reaffirmed their commitment to stakeholders' consultations on the policy matters concerning intellectual property protection. The statement said Prime Minister Narendra Modi and President Obama agreed to strengthen bilateral cooperation in the health sector, including distribution barriers and patent quality, among other areas. Activists in India and the US have claimed that American-style intellectual property rights policy prescriptions could severely hurt the Indian health system, and restrict access to inexpensive generic medicines to patients in India and other developing countries. The activists said Obama, whose first presidential campaign included a prominent pledge to "break the stranglehold" of pharmaceutical companies over access to affordable generic medicines, used the India-US business forum to call for increased intellectual property rights in India. "Indian generics have been essential to expanding access to medicines around the world," Asia Russell, executive director of Health Gap, an international NGO monitoring intellectual property rights policies and impact on access to drugs said in a statement. Sections of health activists in India have said the Indian government has signalled that it is willing to change its stand on medicines, and veer towards the pharmaceutical companies' demand for "data exclusivity" that could curb production of new generic medicines. Data exclusivity would deny generic manufacturers from using any data generated by original companies that have developed new drug molecules. "Such a move would benefit foreign multinational drug companies and leave Indian generic makers in the lurch, risking the health of millions of patients in India and other developing countries," said Anand Grover, director of Lawyers' Collective, a network of lawyers in India that has represented patients' groups and challenged certain decisions on patents in courts. Activists believe India's existing patent laws on medicines have adequate safeguards that need to be rigorously implemented to protect the rights of patients. "It is strange that the Indian government is inviting US inputs on a draft intellectual property rights policy for India," said Kalyani Menon Sen, an activist with the Campaign for Affordable Trastuzumab, a non-government group seeking to lower the price of a drug used against certain types of breast cancer. Representatives of pharmaceutical companies seeking changes in India's intellectual property rights regulations have said the existing laws do not provide adequate recognition to innovation and the investments that go into research and development towards generating new drug molecules. But Mathew Kavanagh, a senior policy analyst with Health Gap, disagreed. "India fully complies with international law while also making it possible for millions of people in India and around the world to access life-saving affordable drugs." He said US drug companies want India to adopt data exclusivity rules that would turn US clinical trial data submitted to drug regulators into a right, and create a barrier to the registration of generics based on that data even when there is no patent on the drug.